PBAC's latest decision on Sildenafil citrate: Recommended (2006). Considered for treatment of adult patients with primary pulmonary hypertension or pulmonary hypertension associated with connective tissue disease (WHO functional Class III).
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
adult patients with primary pulmonary hypertension or pulmonary hypertension associated with connective tissue disease (WHO functional Class III)
Therapy area
Respiratory
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
QoL
Key trials
SUPER-1, BREATHE-1, Study 351, SERAPH
Comparator
bosentan
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis used; no ICER calculated. Incremental cost per metre gained in 6MWT was < $15,000 but this is not an ICER.